[The effect of overall treatment time on local control in nasopharyngeal carcinoma patients treated with intensity modulated radiation therapy]. 2011

Sheng-fa Su, and Fei Han, and Chong Zhao, and Chun-yan Chen, and Wei-wei Xiao, and Jia-xin Li, and Tai-xiang Lu
Department of Radiation Oncology, Sun Yat-Sen University Cancer Center; State Key Laboratory of Oncology in South China Guangzhou, Guangzhou 510060, China.

OBJECTIVE At present, the clinical data about the effect of overall treatment time (OTT) on local control for nasopharyngeal carcinomas (NPC) patients mainly derived from conventional radiotherapy (CRT). The effect of OTT on local control for NPC patients treated with IMRT is still unclear. This study was to explore the effect of OTT on local control in IMRT for NPC patients. METHODS Clinical data of 850 NPC (T1-4N0-3M0) patients that had undergone radical radiotherapy with IMRT from May 2001 to January 2008 in Sun Yat-sen University Cancer Center were analyzed retrospectively. All patients were divided into two groups, which were group with OTT ≤ 42 and group with OTT > 42 days respectively. Survival was calculated using the Kaplan-Meier method. The log-rank test was used to compare survival curves. The effect of clinical factors and treatment related factors on LCR were studied with univariate and multivariate analyses using logistic regression. RESULTS The 5-years local recurrence-free survival (LRFS) rate of group with OTT ≤ 42 were 90.7%, and 90.9% in group with OTT > 42, no significant differences were found between these two groups (χ² = 0.028, P = 0.866). Further stratified analysis found that the LRFS rate for early T-stage patients was no significant difference between group with OTT ≤ 42 and group with > 42 days, they were 97.2% and 97.9% (χ² = 0.672, P = 0.412). For advanced T-stage patients, the LRFS rate of OTT ≤ 42 and > 42 days were 86.5% and 87.2% respectively (χ² = 0.151, P = 0.698). The 5-year LRFS rate were 94.4% vs 93.0% (χ² = 0.090, P = 0.764) at OTT > 42 vs ≤ 42 days for patients treated with IMRT alone, and 89.7% vs 87.6% (χ² = 0.060, P = 0.807) for patients in combination chemotherapy with IMRT. We divided all patients into three groups: OTT ≤ 42 d, 43 - 49 d and ≥ 50 d, the 5-years LRFS rate of the three group was 90.7%, 91.7% and 88.4%, respectively, there was no significant difference of LRFS among those three groups (χ² = 0.136, P = 0.934). Univariate analysis showed that T-stage and GTV volume were correlation with local control. In multivariate analysis, GTV volume was confirmed as independent prognostic factors for local control. CONCLUSIONS Within the range of the OTT observed in our study, prolonged OTT did not have adverse effect on local control. GTV volume was independent prognostic factors in local control for NPC patients treated with IMRT.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009303 Nasopharyngeal Neoplasms Tumors or cancer of the NASOPHARYNX. Cancer of Nasopharynx,Nasopharyngeal Cancer,Cancer of the Nasopharynx,Nasopharynx Cancer,Nasopharynx Neoplasms,Neoplasms, Nasopharyngeal,Cancer, Nasopharyngeal,Cancer, Nasopharynx,Cancers, Nasopharyngeal,Cancers, Nasopharynx,Nasopharyngeal Cancers,Nasopharyngeal Neoplasm,Nasopharynx Cancers,Nasopharynx Neoplasm,Neoplasm, Nasopharyngeal,Neoplasm, Nasopharynx,Neoplasms, Nasopharynx
D002277 Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for "cancer." Carcinoma, Anaplastic,Carcinoma, Spindle-Cell,Carcinoma, Undifferentiated,Carcinomatosis,Epithelial Neoplasms, Malignant,Epithelioma,Epithelial Tumors, Malignant,Malignant Epithelial Neoplasms,Neoplasms, Malignant Epithelial,Anaplastic Carcinoma,Anaplastic Carcinomas,Carcinoma, Spindle Cell,Carcinomas,Carcinomatoses,Epithelial Neoplasm, Malignant,Epithelial Tumor, Malignant,Epitheliomas,Malignant Epithelial Neoplasm,Malignant Epithelial Tumor,Malignant Epithelial Tumors,Neoplasm, Malignant Epithelial,Spindle-Cell Carcinoma,Spindle-Cell Carcinomas,Tumor, Malignant Epithelial,Undifferentiated Carcinoma,Undifferentiated Carcinomas
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077274 Nasopharyngeal Carcinoma A carcinoma that originates in the EPITHELIUM of the NASOPHARYNX and includes four subtypes: keratinizing squamous cell, non-keratinizing, basaloid squamous cell, and PAPILLARY ADENOCARCINOMA. It is most prevalent in Southeast Asian populations and is associated with EPSTEIN-BARR VIRUS INFECTIONS. Somatic mutations associated with this cancer have been identified in NPCR, BAP1, UBAP1, ERBB2, ERBB3, MLL2, PIK3CA, KRAS, NRAS, and ARID1A genes. Carcinoma, Nasopharyngeal,Carcinomas, Nasopharyngeal,Nasopharyngeal Carcinomas
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Sheng-fa Su, and Fei Han, and Chong Zhao, and Chun-yan Chen, and Wei-wei Xiao, and Jia-xin Li, and Tai-xiang Lu
April 2020, Laryngoscope investigative otolaryngology,
Sheng-fa Su, and Fei Han, and Chong Zhao, and Chun-yan Chen, and Wei-wei Xiao, and Jia-xin Li, and Tai-xiang Lu
December 1990, International journal of radiation oncology, biology, physics,
Sheng-fa Su, and Fei Han, and Chong Zhao, and Chun-yan Chen, and Wei-wei Xiao, and Jia-xin Li, and Tai-xiang Lu
January 2015, Radiation oncology (London, England),
Sheng-fa Su, and Fei Han, and Chong Zhao, and Chun-yan Chen, and Wei-wei Xiao, and Jia-xin Li, and Tai-xiang Lu
January 2015, PloS one,
Sheng-fa Su, and Fei Han, and Chong Zhao, and Chun-yan Chen, and Wei-wei Xiao, and Jia-xin Li, and Tai-xiang Lu
August 2021, Annals of translational medicine,
Sheng-fa Su, and Fei Han, and Chong Zhao, and Chun-yan Chen, and Wei-wei Xiao, and Jia-xin Li, and Tai-xiang Lu
March 2016, Scientific reports,
Sheng-fa Su, and Fei Han, and Chong Zhao, and Chun-yan Chen, and Wei-wei Xiao, and Jia-xin Li, and Tai-xiang Lu
June 2015, European annals of otorhinolaryngology, head and neck diseases,
Sheng-fa Su, and Fei Han, and Chong Zhao, and Chun-yan Chen, and Wei-wei Xiao, and Jia-xin Li, and Tai-xiang Lu
April 2019, Radiation oncology (London, England),
Sheng-fa Su, and Fei Han, and Chong Zhao, and Chun-yan Chen, and Wei-wei Xiao, and Jia-xin Li, and Tai-xiang Lu
July 2003, Zhonghua zhong liu za zhi [Chinese journal of oncology],
Sheng-fa Su, and Fei Han, and Chong Zhao, and Chun-yan Chen, and Wei-wei Xiao, and Jia-xin Li, and Tai-xiang Lu
March 2018, Japanese journal of clinical oncology,
Copied contents to your clipboard!